FAQ: Nutriband Inc.'s Innovation in Abuse-Deterrent Drug Delivery and the Opioid Crisis

What is Nutriband Inc.’s AVERSA(TM) technology?

Nutriband’s AVERSA(TM) technology is pioneering the development of the first abuse-deterrent transdermal fentanyl patch, aimed at reducing misuse and addiction risks associated with opioid medications.

Why is there an urgent need for abuse-deterrent opioid delivery methods?

The opioid crisis has highlighted the dangers of misuse, addiction, and overdose, prompting FDA regulatory changes and a demand for safer opioid therapies and responsible prescribing practices.

How does Nutriband’s technology address the opioid crisis?

By developing an abuse-deterrent transdermal fentanyl patch, Nutriband aims to provide a safer method of opioid delivery that reduces the potential for misuse and supports public health efforts to combat the opioid crisis.

What recent FDA regulatory changes affect opioid medications?

Recent changes include the approval of non-opioid painkillers like Journavx, requirements for opioid manufacturers to include prepaid mail-back envelopes for safe disposal, and enhanced boxed warnings on opioid labels.

Who is Nutriband partnering with for the commercialization of AVERSA(TM)?

Nutriband has strategic milestones with partner Kindeva and has strengthened its global IP portfolio to position the company for long-term growth in the abuse-deterrent drug delivery market.

Where can I find more information about Nutriband Inc. and its developments?

The latest news and updates relating to Nutriband Inc. (NASDAQ: NTRB) are available in the company’s newsroom at https://ibn.fm/NTRB.

What are the implications of Nutriband’s technology for the opioid market?

Nutriband’s technology represents a significant advancement in the opioid market by offering a safer alternative that could reduce misuse and align with FDA’s emphasis on improving the safety of opioid therapies.

How does Nutriband’s approach compare to non-opioid alternatives?

While non-opioid alternatives like Journavx provide safer options for pain management, Nutriband’s AVERSA(TM) technology focuses on making existing opioid therapies safer, addressing a critical need in the current opioid landscape.